#News: Eli Lilly and Company Gateway Labs is going global, with the U.K. government announcing today that the nation will host the first European branch of the #incubator program. The #GatewayLabs are co-working spaces for researchers that also act like accelerators. The idea is that companies or researchers that lease space have the opportunity to collaborate on mutually beneficial research and tap into Lilly’s expertise. Lilly already operates two Gateway Labs sites in South San Francisco, as well as cutting the ribbon at a new location at the Lilly Institute for Genetic Medicine in Boston's Seaport district in August. A permanent space in San Diego is expected to open next year. The U.K. will host the first Gateway Labs announced abroad as part of a 279 million pounds sterling ($364 million) investment the U.S. pharma giant is making into the U.K.’s life sciences sector. The agreement with the recently elected U.K. government—announced as part of an International Investment Summit organized by the government today—will be focused on “tackl[ing] significant health challenges,” such as obesity. Read more in Fierce Biotech ???? https://lnkd.in/e-4A6AWK
Rizwan Chaudhrey的动态
最相关的动态
-
Exciting news! Eli Lilly is poised to "build a new way of doing science" in the UK, thanks to a £297m pledge to boost the nation's life sciences sector. ?? Announced at the International Investment Summit in London, this move includes launching the first European Lilly Gateway Labs—an incubator to support early-stage life science start-ups. This initiative will provide companies with access to lab space, equipment, and collaboration opportunities with Lilly scientists. It's a fantastic step forward for the UK's biotech industry! Lilly is leveraging technology like AI to revolutionise pharmaceutical product development. ?? At the BIA TechBio 2024 conference, Senior VP Ramesh Durvasula highlighted how the company is "constantly reinventing" itself using the latest tech. Alongside Lilly Gateway Labs, collaborations such as the recent partnership with insitro aim to develop treatments for metabolic diseases combining machine learning and drug delivery technology. Such initiatives not only foster innovation but also lay the foundation for the next generation of medical breakthroughs. In addition to setting up Lilly Gateway Labs, the funding will support a five-year clinical trial named SURMOUNT-REAL UK. This study will evaluate Mounjaro's effectiveness in weight loss and diabetes prevention, enhancing health outcomes for adults with obesity. Mounjaro was also recommended by NICE and will soon be accessible to those with the greatest clinical need, as per NHS England's phased rollout plan. This commitment signifies a milestone in improving health for people with obesity and related conditions. #Biotech #LifeSciences #Innovation
要查看或添加评论,请登录
-
Exciting news! Eli Lilly is poised to "build a new way of doing science" in the UK, thanks to a £297m pledge to boost the nation's life sciences sector. ?? Announced at the International Investment Summit in London, this move includes launching the first European Lilly Gateway Labs—an incubator to support early-stage life science start-ups. This initiative will provide companies with access to lab space, equipment, and collaboration opportunities with Lilly scientists. It's a fantastic step forward for the UK's biotech industry! Lilly is leveraging technology like AI to revolutionise pharmaceutical product development. ?? At the BIA TechBio 2024 conference, Senior VP Ramesh Durvasula highlighted how the company is "constantly reinventing" itself using the latest tech. Alongside Lilly Gateway Labs, collaborations such as the recent partnership with insitro aim to develop treatments for metabolic diseases combining machine learning and drug delivery technology. Such initiatives not only foster innovation but also lay the foundation for the next generation of medical breakthroughs. In addition to setting up Lilly Gateway Labs, the funding will support a five-year clinical trial named SURMOUNT-REAL UK. This study will evaluate Mounjaro's effectiveness in weight loss and diabetes prevention, enhancing health outcomes for adults with obesity. Mounjaro was also recommended by NICE and will soon be accessible to those with the greatest clinical need, as per NHS England's phased rollout plan. This commitment signifies a milestone in improving health for people with obesity and related conditions. #Biotech #LifeSciences #Innovation
要查看或添加评论,请登录
-
The RHC applauds the Ontario government and AstraZeneca for their significant investment to expand life science research and development, driving growth in Ontario’s life sciences sector. This milestone reflects Ontario’s commitment to its "Taking Life Sciences to the Next Level" strategy, reinforcing its leadership in biomanufacturing and innovation. We are proud to see investments that not only strengthen the development of cutting-edge health technologies but also create new opportunities for the life sciences workforce. The RHC remains dedicated to advancing Canada’s life sciences ecosystem, advocating for innovative solutions that improve care, access, and outcomes for patients. https://lnkd.in/eccGT2q9
要查看或添加评论,请登录
-
?????? ?????? ?????????????????? ???????????????? ???????? ???????????? ?????????? ???? ????????! After a successful prerelease at the SD Biotech Summit and the AURP International Conference in Arkansas, we’re excited to share the final edition of our comprehensive market study. This year’s report dives into South Dakota’s growing strength within the life sciences ecosystem. It highlights: ?????A network of South Dakota FDA-registered facilities. ?????Increasing activity in late-stage oncology clinical trials. ?????Strong support from state resources, organizations, and universities. Together, these factors make South Dakota a compelling destination for scale-up companies in life sciences and medtech—offering a unique combination of affordability and robust resources for growth. ?? Access the full report here: https://lnkd.in/gGbTPb2A
要查看或添加评论,请登录
-
?? Transforming Cardiovascular Care: MONCYTE Health Raises €1M Seed Funding! ?? Helsinki-based Moncyte Health is on a mission to change the game in cardiovascular disease treatment and prevention. Backed by leading investors like Inventure, Almaral, Athensmed, and University of Helsinki Funds, this funding round marks a pivotal step toward precision health. What’s Moncyte Health Doing? ? Proprietary Technology: Providing deep insights into biological processes driving high blood cholesterol, tailored to individual differences. ???? ? Pharma Partnerships: Enabling pharmaceutical companies to better understand how lipid-lowering drugs impact cellular processes linked to cardiovascular risk. ?? Why It Matters: ? Precision in Treatment: Going beyond a one-size-fits-all approach, Moncyte's technology unlocks personalized insights for improved treatment outcomes. ? Proactive Prevention: Empowering the medical community with tools to prevent cardiovascular disease by targeting its biological roots. ???? What’s Next? With CEO Tamara Alagirova at the helm, Moncyte Health is set to amplify its go-to-market strategy and scale its innovative solutions, paving the way for a healthier, heart-smart future. ???? ?? Stay tuned to Future Techly for the latest updates on this groundbreaking initiative and the latest in tech and business! ?? Source: FinSMEs ?? Repost if you think this insight is worth sharing!
要查看或添加评论,请登录
-
-
Learn about the growth issues that lie ahead for the Aus biotech sector with this new discussion paper by AusBiotech and MTPConnect.
?? NEWS: Today AusBiotech and MTPConnect have released a discussion paper on critical life science growth issues ahead of our upcoming National Biotech and Medtech Development and Commercialisation Summit, on 19 November 2024 in Canberra. ? Australia's life sciences sector is an essential part of Australia’s economy, supporting high-paying and skilled jobs, manufacturing exports, and underpinning the health and wellbeing of Australians. It is rightly recognised by the Australian Government as a critical sector that is essential for Australia’s future. Yet while we are in the top ten globally for research, we slip down to 30th for the translation and commercialisation of that research. The upcoming Summit will see AusBiotech and MTPConnect gather some of the country’s most senior leaders from a cross-section of the biotech and medtech sector to tackle these issues.? ? The joint discussion paper launched today unpacks Australian and global policy contexts, stubborn industry challenges, and barriers to achieving robust “Development and Commercialisation” outcomes. MTPConnect CEO Stuart Dignam said the discussion paper and 19 November Summit aim to harness industry insights and create a united voice to government ahead of the 2025 election. “Medical products are one of Australia’s most significant value-add exports, but gaps in biomedical and medical technology product development limit our ability to fully realise the commercial potential of our innovation prowess,” Mr Dignam said. Add your voice to the discussion The Summit is one part of the conversation, and your insights are crucial to ensuring the discussions and any outputs reflect the diverse perspectives of the industry. If you aren’t attending the Summit, we invite you to complete the survey to share your views. Check out the discussion paper and survey below: https://lnkd.in/gmAjHbFp Stuart Dignam, Hon. Jaala Pulford, Rebekah Cassidy, Erin McAllum, Duncan Macinnis, Lisa Dubé, Amelia Vom, Andrew Bowskill, Tracey Wilkinson, Dana Bell
要查看或添加评论,请登录
-
?? Today’s National Biotech and Medtech Development and Commercialisation Summit 2024 in Canberra brings together more than 100 of Australia’s leading industry figures, policy experts, and innovators to shape the future of the nation’s biotech and medtech sectors with a unified voice. AusBiotech CEO, Rebekah Cassidy, said the Summit comes at pivotal time for Australian life sciences companies including innovators, manufacturers and service providers. “The factors influencing life sciences investment and growth are changing rapidly, which is why it’s crucial that AusBiotech leverage its national convening power to elevate the sector’s voice and lead evidenced-based policy discussions. Now is the time for a unified strategy and roadmap focused on enhancing industry’s development and commercialisation capabilities to bring more life changing medical innovations to market.” MTPConnect CEO Stuart Dignam says nurturing a culture of innovation and focus on commercialisation can make all the difference. “We need a coordinated strategy for backing life sciences innovation and supporting startups and SMEs through the difficult early years of innovation so we capture more opportunities to develop and commercialise sovereign medical products that create jobs, exports and health improvements.” Through this Summit, both organisations hope to provide a clear roadmap to government and industry stakeholders that aligns our policies, funding, and capabilities to accelerate the commercialisation of Australian innovations and position Australia as a global leader. Read more about the Summit.... Hon. Jaala Pulford, James Campbell, Karyn McIntosh, Rosanne Hyland, Lisa Dubé, Amelia Vom, Duncan Macinnis, Erin McAllum, Emma Boscheinen, Caroline Duell
要查看或添加评论,请登录
-
"After a difficult three years, biotech financing may slowly be returning to health" By Melanie Senior - Larger but Fewer Rounds, and #Investor Preference:?#biotech funding is shifting towards larger, fewer rounds, with the average round being around $90 million compared to $56 million in 2019. Investors are leaning towards companies with experienced management teams, focusing on de-risked opportunities. - Late-Stage Focus:?Investors are prioritizing late-stage programs, particularly those with in-licensed clinical assets, making it harder for early-stage companies to secure funding. - Hotspots:?#ADCs and RLTs are attracting significant investment, while #CGT are struggling due to unresolved manufacturing and scalability issues. - Series A Shifts:?Series A rounds of $100M+ are becoming common, often focused on #cancer, immunology, obesity (driven by GLP-1 agonists), and neurology. - #AI in Drug Discovery:?There’s still strong investment in AI-driven drug discovery, with tech and biotech investors showing interest. AI has yet to prove its (#clinical) value and impact. - Global #Trends:?The quality of Chinese biotech assets is improving, adding another layer of competition and opportunity in the global market. Regulatory / political pressure to continue.
要查看或添加评论,请登录
-
?? Actio Biosciences Launches with $55M Series A, Partners with Jackson Laboratory TL;DR: ? $55M funding led by Canaan and Droia Ventures ? Strategic partnership with Jackson Laboratory for mouse models ? Initial focus on Charcot-Marie-Tooth disease ? Targeting TRPV4 ion channel protein Exciting developments in the rare disease space! San Diego-based Actio Biosciences is making waves with a dual announcement that's turning heads in biotech. The startup is pioneering a unique approach to drug development, leveraging Mendelian disease research to bridge rare and common disease treatments. Their collaboration with Jackson Laboratory will create advanced mouse models that better mimic human diseases. CEO David Goldstein's strategy? Understanding disease mechanisms first, then developing targeted therapies that could impact both rare and common conditions. Starting with Charcot-Marie-Tooth Type 2C, they're exploring TRPV4's role in both neurodegenerative and bone disorders. Notable industry veterans George Golumbeski and John McHutchinson join as advisors, bringing decades of expertise to guide this promising venture. ?? What are your thoughts on this approach to rare disease drug development? Could this model revolutionize how we bridge rare and common disease treatments? #Biotech #RareDiseases #DrugDevelopment #Innovation #BiotechNews #intelligencesimplified #pharma #biotech #biodatastudio
要查看或添加评论,请登录
-
?? Exciting Developments in West Coast Immunological Biotech! ?? The West Coast is emerging as a leading hub for immunological advancements, shaping the future of biotech. Here's why: Innovation Hubs: Silicon Valley and the San Francisco Bay Area foster a thriving ecosystem where established businesses and startups collaborate to advance immunology. Cutting-Edge Labs and Research Facilities: State-of-the-art facilities equipped with the latest technology accelerate the discovery of immunological medicines through interdisciplinary collaboration in academia, IT, and biotech. Emphasis on Personalized Medicine: Utilizing big data analytics and genomics, organizations are tailoring immune medicines for more effective and targeted treatments. Startup Boom: A surge of innovative firms dedicated to immunology is revolutionizing the sector, attracting global talent and investors. Market Growth: Increasing investment and demand make the West Coast a focal point for investors looking to capitalize on the expanding immunology biotech industry. Join me in celebrating the remarkable progress and potential of West Coast immunological biotech! Let's continue to innovate and collaborate to propel healthcare forward. ?? #WestCoastBiotech #Immunology #Innovation #HealthcareInnovation
要查看或添加评论,请登录